Vaccines, Free Full-Text

Venom immunotherapy (VIT) is administered to allergic patients to reduce the risk of dangerous systemic reactions following an insect sting. To better understand the mechanism of this treatment and its impact on the human organism, we analysed serum proteomic patterns obtained at five time-points from Hymenoptera-venom-allergic patients undergoing VIT. For statistical analyses, patients were additionally divided into two groups (high responders and low responders) according to serum sIgG4 levels. VIT was found to be associated with changes in seven proteins: the fibrinogen alpha chain, complement C4-A, complement C3, filamin-B, kininogen-1, myosin-9 and inter-alpha-trypsin inhibitor heavy chain H1. The number of discriminative m/z (mass-to-charge ratio) features increased up to the 90th day of VIT, which may be associated with the development of immunity after the administration of increased venom doses. It may also suggest that during VIT, there may occur processes involved not only in protein synthesis but also in protein degradation (caused by proteolytic venom components). The results are consistent with measured serum sIgG4 levels, which increased from 2.04 mgA/I at baseline to 7.25 mgA/I at 90 days. Moreover, the major proteomic changes were detected separately in the high responder group. This may suggest that changes in protein–peptide profiles reflect the actual response to VIT.

COVID-19 Vaccine La Dept. of Health

IJERPH, Free Full-Text

Human Vaccines & Immunotherapeutics: Vol 19, No 3 (Current issue)

Information and facts about about COVID-19 vaccines Archives

The EFIS vaccination task force expert report - Sarantopoulos

COVID-19 mRNA vaccines: Platforms and current developments

Public attitudes toward COVID-19 vaccination: The role of vaccine

Frontiers Impact of Vaccines; Health, Economic and Social

Facts about the COVID-19 Vaccines for adults